Immunity and morbidity in Schistosoma mansoni infection: quantitative aspects
- PMID: 8940963
- DOI: 10.4269/ajtmh.1996.55.109
Immunity and morbidity in Schistosoma mansoni infection: quantitative aspects
Abstract
Immunity to Schistosoma mansoni infection in humans can be studied most easily by monitoring serially the intensity of reinfection that occurs among individuals who have undergone chemotherapeutic cure, and whose levels of exposure to contaminated water is subsequently observed. Parallel studies can then be made of those immune responses that are correlated with an observed resistance to reinfection. This paper describes some of the difficulties associated with this approach, with particular reference to the authors' own studies in Kenya, and highlights a possible role of immunoglobulin E antibodies against adult worm antigens in mediating immunity.
Similar articles
-
Human IgE responses to Schistosoma mansoni and resistance to reinfection.Mem Inst Oswaldo Cruz. 1992;87 Suppl 4:99-103. doi: 10.1590/s0074-02761992000800014. Mem Inst Oswaldo Cruz. 1992. PMID: 1343933
-
Development of antibody isotype responses to Schistosoma mansoni in an immunologically naive immigrant population: influence of infection duration, infection intensity, and host age.Infect Immun. 1999 Jul;67(7):3444-51. doi: 10.1128/IAI.67.7.3444-3451.1999. Infect Immun. 1999. PMID: 10377125 Free PMC article.
-
Immunity and morbidity in human schistosomiasis mansoni.Trop Geogr Med. 1994;46(4 Spec No):197-208. Trop Geogr Med. 1994. PMID: 7825222 Review.
-
Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal.Trop Geogr Med. 1994;46(4 Spec No):209-19. Trop Geogr Med. 1994. PMID: 7825223 Clinical Trial.
-
Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control.Immunol Invest. 1992 Aug;21(5):391-407. doi: 10.3109/08820139209069381. Immunol Invest. 1992. PMID: 1428017 Review.
Cited by
-
Vaccine value profile for schistosomiasis.Vaccine. 2024 Jul 23:126020. doi: 10.1016/j.vaccine.2024.05.068. Online ahead of print. Vaccine. 2024. PMID: 39592316
-
Susceptibility of dendritic cells from individuals with schistosomiasis to infection by Leishmania braziliensis.Mol Immunol. 2018 Jan;93:173-183. doi: 10.1016/j.molimm.2017.11.018. Epub 2017 Nov 29. Mol Immunol. 2018. PMID: 29197260 Free PMC article.
-
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.Clin Exp Allergy. 2007 Feb;37(2):197-207. doi: 10.1111/j.1365-2222.2007.02650.x. Clin Exp Allergy. 2007. PMID: 17250692 Free PMC article. Clinical Trial.
-
Polarized Th2 like cells, in the absence of Th0 cells, are responsible for lymphocyte produced IL-4 in high IgE-producer schistosomiasis patients.BMC Immunol. 2002 Jul 6;3:8. doi: 10.1186/1471-2172-3-8. BMC Immunol. 2002. PMID: 12100735 Free PMC article.
-
Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice.Antimicrob Agents Chemother. 2003 Dec;47(12):3853-8. doi: 10.1128/AAC.47.12.3853-3858.2003. Antimicrob Agents Chemother. 2003. PMID: 14638494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources